A Basket Study of CTA313 in Participants With Active Autoimmune Diseases (ALLNEW)
A Single-Arm, Open-Label, Multi-Center, Phase Ib Basket Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTA313 in Participants With Active Autoimmune Diseases
The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders.
Participants with SLE, pMS and AIE between the ages of 18 and 75 will be eligible to participate.
Participants will receive one infusion of CTA313 on Day 0. During the Dose Confirmation portion, cohorts will be independently evaluated for safety and to establish the RP2D of CTA313. During the Cohort Expansion portion of the study patients will be evaluated to further confirm the efficacy and safety of CTA313.
Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Jan Davidson-Moncada, MD, PhD
- 电话号码:917-573-8538
- 邮箱:clinicaltrials@imvivabio.com
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Key Inclusion Criteria:
- Male or female, ≥ 18 and ≤ 75 years of age
- Adequate organ function
Diagnosed with one of the following in addition to meeting disease-specific criteria:
- Refractory Systemic Lupus Erythematosus (SLE) defined as an inadequate response to at least two immunomodulatory agents and one biologic agent
- Primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
- Autoimmune Encephalitis (AIE)
Key Exclusion Criteria:
- Coexisting autoimmune diseases that could interfere with the attribution of disease activity or pose an increased safety risk
Participants with the following cardiac conditions are excluded:
- History of heart failure New York Heart Association (NYHA) class III or IV;
- History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.
- History of severe central nervous system (CNS) disorders that could compromise the participant's ability to comply with protocol requirements or interfere with the accuracy of study assessments
- Current or prior malignancy unless the malignancy was treated with curative intent and the subject has no known active malignant disease present for ≥ 5 years before enrollment
- Primary immune deficiency
- Presence of uncontrolled infections
- History of untreated hepatitis C virus, or syphilis
- History of HIV infection, or active or latent hepatitis B virus (HBV) infection.
- Evidence of active Epstein-Barr virus (EBV), cytomegalovirus (CMV) or tuberculosis (TB)
- History of prior CAR-T cell therapy or any other genetically modified immune cell therapy
- Having received live/attenuated vaccine within 4 weeks prior to enrollment
- Participants with a history of hypersensitivity to tacrolimus
- Those who have participated in other interventional clinical trials within 30 days before enrollment
- Participants who meet disease-specific exclusionary criteria as specified
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:CTA313 UCAR T Cell Infusion
|
CAR T cells
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety Profile
大体时间:24 months
|
Incidence and severity of adverse events including dose limiting toxicities
|
24 months
|
|
RP2D Determination
大体时间:24 months
|
Determine the RP2D based on safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy.
|
24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Preliminary Efficacy - SLE
大体时间:24 months
|
Proportion of participants achieving DORIS and LLDAS
|
24 months
|
|
Preliminary Efficacy - pMS
大体时间:24 months
|
Proportion of patients without disability progression as defined by change in EDSS
|
24 months
|
|
Preliminary Efficacy - AIE
大体时间:24 months
|
Proportion of patients achieving functional improvement and/or response by modified Rankin Scale (mRS)
|
24 months
|
|
Characterize the cPK profile of CTA313
大体时间:24 months
|
Evaluate CTA313 cellular pharmacokinetic (PK) by measuring expansion, distribution and persistence
|
24 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BHCT-CTA313-101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.